Extreme mutational selectivity of axitinib limits its potential use as a targeted therapeutic for BCR-ABL1-positive leukemia

M. S. Zabriskie, C. A. Eide, D. Yan, N. A. Vellore, A. D. Pomicter, S. L. Savage, B. J. Druker, M. W. Deininger, T. O'Hare

Research output: Contribution to journalLetterpeer-review

9 Scopus citations
Original languageEnglish (US)
Pages (from-to)1418-1421
Number of pages4
Issue number6
StatePublished - Jun 1 2016

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Cancer Research

Cite this